Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 88 clinical trials
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.

mental disorders
stem cell transplantation
bcma
remission
ejection fraction
  • 0 views
  • 27 Feb, 2022
  • 1 location
Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma

(multiple myeloma). BCMA (B cell maturation antigen) is a promising target for malignant plasma cells. Therefore, we designed a clinical trial using anti-BCMA CAR-T cell therapy for patients with relapsed

  • 0 views
  • 26 Jan, 2021
  • 1 location
Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma

This is a Phase 1, multicenter, open-label study o evaluate the safety and efficacy of CART-BCMA in subjects with relapsed/refractory multiple myeloma.

refractory multiple myeloma
  • 0 views
  • 10 May, 2022
  • 2 locations
Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma

The purpose of this study is to infuse BCMA CAR-NK cellsUmbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells to the patients with relapsed and refractory multiple myeloma (MM), to

  • 0 views
  • 28 Nov, 2021
  • 1 location
Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

This Phase I/II study will test the safety and anti-myeloma activity of ascending doses of Descartes-08 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible

cyclophosphamide
immunomodulatory imide drug
bone marrow procedure
platelet count
proteasome inhibitor
  • 47 views
  • 27 Feb, 2022
  • 3 locations
Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma

This is a single-arm, non-randomized, open-label study to confirm the RP2D (recommended phase 2 dose) of GC012F injection in patients with Relapsed/Refractory multiple myeloma (RRMM).

refractory multiple myeloma
  • 0 views
  • 09 Aug, 2022
  • 1 location
MagnetisMM-8: Study Of Elranatamab (PF-06863135) Monotherapy in Chinese Participants With Refractory Multiple Myeloma

stage design to evaluate the efficacy and safety in Chinese participants. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma

refractory multiple myeloma
  • 0 views
  • 25 Jul, 2022
  • 8 locations
Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma

This is a single center, non-randomized, open-label, phase 2 study to evaluate the efficacy and safety of BCMA-PD1-CART cells therapy for patients with relapsed/refractory Multiple Myeloma.

refractory multiple myeloma
immunohistochemistry
fludarabine
bcma
remission
  • 7 views
  • 17 Feb, 2022
  • 1 location
Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.

mental disorders
stem cell transplantation
bcma
remission
ejection fraction
  • 0 views
  • 27 Feb, 2022
  • 1 location
A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Clinical Trial for the safety and efficacy of BCMA-targeted CAR-T cells therapy for refractory/relapsed multiple myeloma

  • 0 views
  • 14 Jul, 2022
  • 1 location